“I was especially encouraged by the shared view among the board members that we truly have a unique solution that addresses clear needs in pharmaceutical development. Accurately quantifying low levels of biological markers is essential for understanding drug mechanisms and identifying patients eligible for treatment”, comments Sanna Wallenborg, CEO of Lumito.

The discussions focused on two strategic areas: accelerating go-to-market activities and exploring applications within the pharmaceutical development sector. The board expressed strong consensus that Lumito has demonstrated solid proof of product and is currently in the proof of business phase, following the CE marking of Scizys.

“Adding Pascal Bamford to our, already highly regarded SAB, is truly an honour. His competence and experience in our field, including market introduction of new technologies as well as nanoparticles and image analysis proved its value already in this first SAB. I am looking forward to future interactions with Pascal and the rest of our advisory board”, finishes Sanna Wallenborg.

Pascal Bamford, PhD – technical expert in image analysis, digital pathology and oncology diagnostics with over 25 years of experience. Has held leadership roles at Roche Tissue Diagnostics, Epic Sciences and Akoya Biosciences. Currently Chief Clinical Officer at Akoya Biosciences.

Chair of the SAB, Paul Waring, shares highlights from the meeting in a video summary, link here.